Volltext-Artikel, E-Books und Literaturhinweise aus dem EBSCO Discovery Service

"Artikel & mehr" berücksichtigt nur einen Teil der für die Bibliothek der Frankfurt UAS verfügbaren Datenbanken. Zur Übersicht in DBIS

Ergebnis verändern

einschränken: Volltextzugriff; Academic (peer-reviewed) journals
erweitern: Auch Volltexte der Artikel durchsuchen; Verwandte Themen suchen

Publikationstyp

Thema

erschienen in

Verlag

Geographic terms

Sprache

Datenbank

mehr ...

Erscheinungsjahr

Von:

Bis:

Treffer 1 - 25 von 1040, Suchdauer: 0.67s

12 3 4 5 6 7 8 9 10 11 weiter »

1
Long-term outcomes from pembrolizumab monotherapy in patients with advanced NSCLC, PD-L1 expression ≥ 50 %, and poor performance status: Transformer-based AI to characterize prognostic complexity

von Cortellini, Alessio ; Garbo, Edoardo ; La Cava, Giulia ; et al.

In Lung Cancer November 2025 209
- View full text via DOI
Merkliste

2
Dieses Ergebnis aus Science Citation Index Expanded kann Gästen nicht angezeigt werden.
Login für vollen Zugriff.
- Zur Referenz in Web of Science
Merkliste

3
Activity of Brigatinib in Patients With Crizotinib-Resistant ALK-positive Non–Small-Cell Lung Cancer According to ALK Fusion and Mutation Status

von Bazhenova, Lyudmila ; Hodgson, J.G. ; Camidge, D. Ross ; et al.

In Clinical Lung Cancer May 2025
- View full text via DOI
Merkliste

4
Transformer-based AI approach to unravel long-term, time-dependent prognostic complexity in patients with advanced NSCLC and PD-L1 ≥50%: insights from the pembrolizumab 5-year global registry

von Cortellini, Alessio ; Santo, Valentina ; Brunetti, Leonardo ; et al.

Schlagworte: Immune Checkpoint Inhibitor; Immunotherapy; Lung Cancer; Survivorship
- View full text via BASE
Merkliste

5
Co-Occurring Alterations in Multiple Tumor Suppressor Genes Are Associated With Worse Outcomes in Patients With EGFR-Mutant Lung Cancer

von Stockhammer, Paul ; Grant, Michael ; Wurtz, Anna ; et al.

In Journal of Thoracic Oncology February 2024 19(2):240-251
- View full text via DOI
Merkliste

6
Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry

von Ricciuti, Biagio ; Naqash, Abdul Rafeh ; Nassar, Amin H ; et al.

Journal for ImmunoTherapy of Cancer, Vol. 13, no.2, p. e010674 (2025)

Schlagworte: Pembrolizumab monotherapy; non-small cell lung cancer (NSCLC); programmed cell death-ligand 1 (PD-L1)
- View full text via BASE
Merkliste

7
First-Line Treatment of Driver-Negative Non–Small Cell Lung Cancer

von Kim, So Yeon ; Gettinger, Scott

In Hematology/Oncology Clinics of North America June 2023 37(3):557-573
- Volltextverfügbarkeit prüfen (via ReDI)
Merkliste

8
Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials : results from the Pembro-real 5Y global registry

von Cortellini, Alessio ; Brunetti, Leonardo ; Di Fazio, Giuseppina Rita ; et al.

ISSN: 2051-1426 ; Journal for immunotherapy of cancer, vol. 13, no. 2 (2025) e010674.

Schlagworte: info:eu-repo/classification/ddc/616; Immune Checkpoint Inhibitor; Immunotherapy; Lung Cancer; Humans; Carcinoma; Non-Small-Cell Lung / drug therapy; Non-Small-Cell Lung / mortality; Non-Small-Cell Lung / pathology; Male; Antibodies; Monoclonal; Humanized / therapeutic use; Female; Lung Neoplasms / drug therapy; Lung Neoplasms / mortality; Lung Neoplasms / pathology; Aged; Middle Aged; Registries; B7-H1 Antigen / antagonists & inhibitors; B7-H1 Antigen / metabolism; Antineoplastic Agents; Immunological / therapeutic use; Adult; 80 and over
- View full text via BASE
Merkliste

9
Dieses Ergebnis aus Science Citation Index Expanded kann Gästen nicht angezeigt werden.
Login für vollen Zugriff.
- Zur Referenz in Web of Science
Merkliste

10
Long-Term Efficacy and Safety of Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Final Results of the Phase 1/2 and Randomized Phase 2 (ALTA) Trials

von Gettinger, Scott N. ; Huber, Rudolf M. ; Kim, Dong-Wan ; et al.

In JTO Clinical and Research Reports September 2022 3(9)
- View full text via DOI
Merkliste

11
Microwave Ablation versus Stereotactic Body Radiotherapy for Stage I Non–Small Cell Lung Cancer: A Cost-Effectiveness Analysis

von Wu, Xiao ; Uhlig, Johannes ; Blasberg, Justin D. ; et al.

In Journal of Vascular and Interventional Radiology August 2022 33(8):964-971
- Volltextverfügbarkeit prüfen (via ReDI)
Merkliste

12
Lifileucel, an Autologous Tumor-infiltrating Lymphocyte Monotherapy, in Patients with Advanced Non-small Cell Lung Cancer Resistant to Immune Checkpoint Inhibitors.

von Schoenfeld, Adam J ; Lee, Sylvia M ; Doger de Speville, Bernard ; et al.

Schoenfeld, Adam J; Lee, Sylvia M; Doger de Speville, Bernard; Gettinger, Scott N; Hafliger, Simon; Sukari, Ammar; Papa, Sophie; Rodriguez-Moreno, Juan Francisco; Graf Finckenstein, Friedrich; Fiaz, Rana; Catlett, Melissa; Chen, Guang; Qi, Rongsu; Masteller, Emma L; Gontcharova, Viktoria; He, Kai (2024). Lifileucel, an Autologous Tumor-infiltrating Lymphocyte Monotherapy, in Patients with Advanced Non-small Cell Lung Cancer Resistant to Immune Checkpoint Inhibitors. Cancer discovery, 14(8), pp. 1389-1402. American Association for Cancer Research 10.1158/2159-8290.CD-23-1334

Schlagworte: 610 Medicine & health
- View full text via BASE
Merkliste

13
Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I Trial.

von Parra, Edwin ; Zhang, Jiexin ; Duose, Dzifa ; et al.

Clinical Cancer Research, vol 30, iss 8

Schlagworte: Humans; Nivolumab; Lung Neoplasms; Multiomics; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Non-Small-Cell Lung; Squamous Cell; Immunotherapy; Lung; Epithelial Cells; Ipilimumab; Tumor Microenvironment
- View full text via BASE
Merkliste

14
Mesothelioma: Pleural, Version 1.2024 ; Featured Updates to the NCCN Guidelines

von Stevenson, James ; Ettinger, David S. ; Wood, Douglas E. ; et al.

Journal of the National Comprehensive Cancer Network ; volume 22, issue 2, page 72-81 ; ISSN 1540-1405 1540-1413
- View full text via BASE
Merkliste

15
Brigatinib Versus Crizotinib in ALK Inhibitor–Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial

von Camidge, D. Ross ; Kim, Hye Ryun ; Ahn, Myung-Ju ; et al.

In Journal of Thoracic Oncology December 2021 16(12):2091-2108
- View full text via DOI
Merkliste

16
Immune Therapy: What Can We Learn From Acquired Resistance?

von Grant, Michael J. ; Politi, Katerina ; Gettinger, Scott ; et al.

Lung Cancer : New Understandings and Therapies. :75-114
- Volltextverfügbarkeit prüfen (via ReDI)
Merkliste

17
A Dose-finding Study Followed by a Phase II Randomized, Placebo-controlled Trial of Chemoradiotherapy With or Without Veliparib in Stage III Non–small-cell Lung Cancer: SWOG 1206 (8811)

von Argiris, Athanassios ; Miao, Jieling ; Cristea, Mihaela C. ; et al.

In Clinical Lung Cancer July 2021 22(4):313-323
- View full text via DOI
Merkliste

18
923 Characterization and clinical significance of the intra and inter-tumor spatial immune heterogeneity using 3-dimensional multiplexed phenotyping in non-small cell lung cancer

von Rodas, Miguel Lopez de ; Frohock, Zachary ; Liu, Xiao ; et al.

Regular and Young Investigator Award Abstracts ; page A1026-A1026
- View full text via BASE
Merkliste

19
Dieses Ergebnis aus Science Citation Index Expanded kann Gästen nicht angezeigt werden.
Login für vollen Zugriff.
- Zur Referenz in Web of Science
Merkliste

20
Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis

von Antonia, Scott J ; Borghaei, Hossein ; Ramalingam, Suresh S ; et al.

In The Lancet Oncology October 2019 20(10):1395-1408
- View full text via DOI
Merkliste

21
Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry

von Cortellini, A ; Brunetti, L ; Di Fazio, G ; et al.

Schlagworte: Immune Checkpoint Inhibitor; Immunotherapy; Lung Cancer; info:eu-repo/semantics/article
- Zum Volltext über OAIster
Merkliste

22
Transformer-based AI approach to unravel long-term, time-dependent prognostic complexity in patients with advanced NSCLC and PD-L1 ≥50%: insights from the pembrolizumab 5-year global registry

von Cortellini, A ; Santo, V ; Brunetti, L ; et al.

Schlagworte: Immune Checkpoint Inhibitor; Immunotherapy; Lung Cancer; Survivorship; info:eu-repo/semantics/article
- Zum Volltext über OAIster
Merkliste

23
Clinical Activity and Safety of Atezolizumab in a Phase 1 Study of Patients With Relapsed/Refractory Small-Cell Lung Cancer

von Chiang, Anne C. ; Sequist, Lecia Van Dam ; Gilbert, Jill ; et al.

In Clinical Lung Cancer September 2020 21(5):455-463
- View full text via DOI
Merkliste

24
NTRK1 Fusions identified by non-invasive plasma next-generation sequencing (NGS) across 9 cancer types

von Rolfo, Christian ; Drilon, Alexander ; Hong, David ; et al.

British Journal of Cancer. 126(3):514-520
- Zum Volltext in PubMed Central
Merkliste

25
Long-term outcomes from pembrolizumab monotherapy in patients with advanced NSCLC, PD-L1 expression ≥ 50 %, and poor performance status: Transformer-based AI to characterize prognostic complexity

von Cortellini, A ; Garbo, E ; La Cava, G ; et al.

Schlagworte: artificial intelligence (AI); ECOG PS 2; Immunotherapy; Long-term outcome; NSCLC; Real-world data; info:eu-repo/semantics/article
- Zum Volltext über OAIster
Merkliste

12 3 4 5 6 7 8 9 10 11 weiter »

Sie haben nicht gefunden, wonach Sie gesucht haben? Diese Services können Ihnen weiterhelfen.
Hilfe & Kontakt ǀ Fernleihe | Hilfe zur Fernleihe ǀ Literaturvorschlag| Literaturvorschlag